Mind Medicine Stock Performance
| MNMD Stock | USD 7.09 0.43 5.72% |
On a scale of 0 to 100, Mind Medicine holds a performance score of 5. The company secures a Beta (Market Risk) of 3.35, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mind Medicine will likely underperform. Please check Mind Medicine's treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Mind Medicine's current price movements will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Mind Medicine are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak primary indicators, Mind Medicine exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.86) | Five Day Return (19.67) | Year To Date Return 99.72 | Ten Year Return 113.91 | All Time Return 113.91 |
Last Split Factor 1:15 | Dividend Date 2020-02-27 | Last Split Date 2022-08-29 |
1 | Disposition of 32595 shares by Halperin Wernli Miri of Mind Medicine at 6.17 subject to Rule 16b-3 | 09/03/2024 |
2 | OurPsychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16 percent In August | 09/06/2024 |
3 | Psychedelic Drug Stocks 6 percent Last Week Vs. -13 percent Previous Week | 09/16/2024 |
4 | Disposition of 4430 shares by Sullivan Mark of Mind Medicine at 5.98 subject to Rule 16b-3 | 09/25/2024 |
5 | MindMed executive sells over 26k in company stock | 09/26/2024 |
6 | Disposition of 1264 shares by Robert Barrow of Mind Medicine at 5.51 subject to Rule 16b-3 | 10/11/2024 |
7 | Mind Medicine Coverage Initiated at Leerink Partners | 10/14/2024 |
8 | MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update | 10/24/2024 |
9 | Acquisition by Wernli Miri Halperin of 100000 shares of Mind Medicine subject to Rule 16b-3 | 11/04/2024 |
10 | Mind Medicine Inc Q3 2024 Earnings Call Highlights Strong Cash Position and Clinical ... | 11/08/2024 |
11 | MindMed to Participate in Upcoming Investor Conferences | 11/13/2024 |
12 | MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer | 11/18/2024 |
| Begin Period Cash Flow | 142.1 M |
Mind |
Mind Medicine Relative Risk vs. Return Landscape
If you would invest 612.00 in Mind Medicine on August 24, 2024 and sell it today you would earn a total of 97.00 from holding Mind Medicine or generate 15.85% return on investment over 90 days. Mind Medicine is currently generating 0.3422% in daily expected returns and assumes 4.7239% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Mind, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mind Medicine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mind Medicine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mind Medicine, and traders can use it to determine the average amount a Mind Medicine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0724
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MNMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.72 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Mind Medicine is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mind Medicine by adding it to a well-diversified portfolio.
Mind Medicine Fundamentals Growth
Mind Stock prices reflect investors' perceptions of the future prospects and financial health of Mind Medicine, and Mind Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mind Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 280.48 M | ||||
| Shares Outstanding | 73.33 M | ||||
| Price To Book | 2.10 X | ||||
| EBITDA | (92.57 M) | ||||
| Net Income | (95.73 M) | ||||
| Cash And Equivalents | 105.74 M | ||||
| Cash Per Share | 3.71 X | ||||
| Total Debt | 14.13 M | ||||
| Current Ratio | 13.86 X | ||||
| Book Value Per Share | 3.21 X | ||||
| Cash Flow From Operations | (64.36 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 551.45 M | ||||
| Total Asset | 124.54 M | ||||
| Retained Earnings | (290.2 M) | ||||
| Working Capital | 71.63 M | ||||
About Mind Medicine Performance
By analyzing Mind Medicine's fundamental ratios, stakeholders can gain valuable insights into Mind Medicine's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mind Medicine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mind Medicine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.92) | (0.97) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.77) | (0.81) | |
| Return On Equity | (1.23) | (1.29) |
Things to note about Mind Medicine performance evaluation
Checking the ongoing alerts about Mind Medicine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mind Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mind Medicine had very high historical volatility over the last 90 days | |
| Net Loss for the year was (95.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mind Medicine currently holds about 105.74 M in cash with (64.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71. | |
| Mind Medicine has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer |
- Analyzing Mind Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mind Medicine's stock is overvalued or undervalued compared to its peers.
- Examining Mind Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mind Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mind Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mind Medicine's stock. These opinions can provide insight into Mind Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mind Stock analysis
When running Mind Medicine's price analysis, check to measure Mind Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mind Medicine is operating at the current time. Most of Mind Medicine's value examination focuses on studying past and present price action to predict the probability of Mind Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mind Medicine's price. Additionally, you may evaluate how the addition of Mind Medicine to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |